(Q35741377)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15072602%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

review article

1 reference

title

Abarelix (Plenaxis): a gonadotropin-releasing hormone antagonist for medical castration in patients with advanced prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15072602%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

G Kesava Reddy

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15072602%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

1 March 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15072602%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

published in

Clinical prostate cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15072602%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15072602%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15072602%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

209-211

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15072602%20AND%20SRC:MED&resulttype=core&format=json

Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders

26 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1540-0352%2811%2970046-4

7 January 2021

Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS1540-0352%2811%2970046-4

7 January 2021

Development of GnRH antagonists for prostate cancer: new approaches to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1540-0352%2811%2970046-4

7 January 2021

A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1540-0352%2811%2970046-4

7 January 2021

A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1540-0352%2811%2970046-4

7 January 2021

10.1016/S1540-0352(11)70046-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15072602%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference